Drug intelligence / Profile preview

cefotaxime + sulbactam

Development stage
Unknown
Lead developer
Shenzhen Salubris Pharmaceuticals
Modality
Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Cefotaxime + sulbactam is a combination antibiotic used to treat a wide range of serious bacterial infections. Cefotaxime is a third-generation cephalosporin antibiotic that works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Sulbactam is a beta-lactamase inhibitor that protects cefotaxime from degradation by beta-lactamase enzymes produced by resistant bacteria, thereby extending the spectrum of activity of cefotaxime. This combination is effective against both gram-positive and gram-negative bacteria, including some beta-lactamase-producing strains. It is commonly administered via intravenous or intramuscular injection for conditions such as respiratory tract infections (including pneumonia), urinary tract infections, skin and soft tissue infections, bone and joint infections, intra-abdominal infections (such as peritonitis), gynecological infections (including pelvic inflammatory disease), septicemia, meningitis, and for surgical prophylaxis[2][3][4][6].

Brand names
Clafoxy-S
Other names
cefotaxime and sulbactamcefotaxime/sulbactam
02

Targets

KPC (Klebsiella pneumoniae carbapenemase)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cefotaxime + sulbactam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefotaxime + sulbactam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call